CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

CRISPR Therapeutics AGNASDAQ: CRSP

Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026

Other income / expenses dips below year-ago levels

Q3 FY2026 other income / expenses of $18.68M fell 28.8% year over year, behind the +1284.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 24.1% from the prior quarter.

Context

  • Other income / expenses amounted to 274.8% of revenue in FY2025, down 22.0 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -28.8% toward the trailing-twelve-month pace of +1284.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$18.68M-24.1% QoQ
Last fiscal yearDec 2025
-$9.65M-109.3% YoY
LTMSep 2026
$76.21M+1284.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.8%——
1 year-109.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(9.65M) USD
Year-over-year change
-109.3%

Other Income / Expenses vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 other income / expenses of $76.21M is the 2nd highest of the 7 companies compared; the peer median is $2.49M.
  • Its year-over-year change of +1284.2% is the highest of 7, against a peer median of +0.4%.
  • Other income / expenses amounts to 302.7% of revenue for CRSP, versus a peer median of 26.9%.
CRSP Competitors Peer median
Other Income / Expenses for CRSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BEAMBeam Therapeutics Inc.LTM Jun 2026$292.6M +517.4%+79.2%187.5%
CRSPCRISPR Therapeutics AGLTM Sep 2026$76.21M +1284.2%—302.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$26.12M +72.4%—39.5%
EDITEditas Medicine, Inc.LTM Mar 2026$6.16M -32.3%—15.9%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-$1.19M +33.1%-73.2%0.8%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$5.37M -124.3%—11.9%
RGNXREGENXBIO Inc.LTM Mar 2026-$33.33M -9907.5%—37.9%
Peer median (excluding CRSP) $2.49M+0.4%+3.0%26.9%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue913.08M436K370M35M3.51M
Cost of Revenue101.18M110.25M130.25M110.25M232.96M
Gross Profit811.9M(109.81M)239.75M(75.25M)(229.45M)
Gross Margin88.9%-25186.7%64.8%-215.0%-6537.0%
Research & Development340.57M461.65M387.33M320.65M265.33M
Selling, General & Admin99.69M102.46M76.16M72.98M73.54M
Operating Expenses438.38M563.35M462.29M391.32M338.87M
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
EBITDA397.48M(626.33M)(130.89M)(343.41M)(558.49M)
EBITDA Margin43.5%-143653.2%-35.4%-981.2%-15911.3%
Operating Income373.53M(673.16M)(222.54M)(466.57M)(568.32M)
Operating Margin40.9%-154394.7%-60.1%-1333.0%-16191.4%
Interest Income00000
Interest Expense00000
Other Income / Expenses6M22.66M71.82M103.9M(9.65M)
Income Before Tax379.53M(650.5M)(150.72M)(362.67M)(577.97M)
Pre-Tax Margin41.6%-149197.2%-40.7%-1036.2%-16466.2%
Income Tax Expense1.87M(325K)2.89M3.59M3.63M
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Net Margin41.4%-149122.7%-41.5%-1046.4%-16569.8%
EPS (Basic)4.97(8.36)(1.94)(4.34)(6.47)
EPS (Diluted)4.70(8.36)(1.94)(4.34)(6.47)
Weighted Avg Shares75.95M77.75M79.22M84.36M89.93M
Weighted Avg Shares (Diluted)80.39M77.75M79.22M84.36M89.93M

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.